U.S. Wheat ETF Runs Out of Shares Due to Rush of Demand

image

(Bloomberg) — Until this month, the only U.S. exchange-traded fund tracking wheat had never lured more than $35 million in a single day. On Friday alone, it added five times that amount.

The Teucrium Wheat Fund (ticker WEAT) gathered almost $183 million at the end of last week as futures soared following Russia’s invasion of Ukraine. That historic flow caused an unusual problem for the ETF — it ran out of shares.

Ordinarily, ETFs can constantly create or redeem shares depending on demand. But WEAT is a so-called commodity pool, which have a pre-set number and require regulatory permission to generate more. With demand still strong on Monday, the fund temporarily halted the creation of more shares pending the approval of the U.S. Securities and Exchange Commission.

“The market will be notified as soon as we are able to resume issuing shares,” said Jake Hanley, managing director at Teucrium.

Wheat, a key food staple, fell 2.9% to $12.49 a bushel on Wednesday in Chicago after reaching a record high in the previous session. Russia and Ukraine represent 29% of global trade in the commodity, according to Bank of America Corp., and rising prices of the commodity may tighten broader agricultural markets.

Other supplies from corn to sunflower oil have also seen their prices spike, further stoking fears of food inflation as the global economy recovers from the depths of the pandemic.

As of Monday, WEAT had around 7,375,000 shares registered with the regulatory agency, according to its filing. Investors can still buy and sell shares of the $483 million fund in the secondary market, and redemption requests will continue to be accepted, the issuer said.

WEAT’s settlement schedule means flow data arrives with a one-day lag. The fund added another $82 million on Monday, the latest data show.

©2022 Bloomberg L.P.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More